Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2020

View Archived Issues

Ditching PAMs expands CRISPR

In blood stem cells, selection drives driver mutations early on

FDA accepts IND application for OTQ-923

Johnson & Johnson announces new lead COVID-19 vaccine candidate

Positive phase II data for THN-102 in patients with Parkinson's disease and EDS

DSR-141562 shows promise in preclinical schizophrenia-related behavioral assays

DIF-1 shows antimetastatic effects in malignant melanoma cells

CRMP2 as a novel biomarker for schizophrenia

Researchers mimic interstitial cystitis in rat model

Biochemical Agent describes IGF-1 long chimeric proteins

New potent and selective ATP-competitive mTOR inhibitor with brain penetrance for CNS disorders

Ohio State University patents lipid nanoparticles modulating Bcl-2, Akt-1

Novel series of sulfamoylbenzamides modulating capsid assembly to target hepatitis B virus infection

Yale University, Arvinas Operations disclose new PROTAC compounds

Primmune selects PRTX-007 for development for SARS-CoV-2 prophylaxis

New RIP-1 inhibitors identified at Bristol-Myers Squibb

FORMA Therapeutics identifies new pyruvate kinase PKLR activators

Accelerated by COVID-19, science changes will outlast pandemic

Step-1 primary endpoint met in phase III Atalante 1 trial of Tedopi in NSCLC

FDA approves Sevenfact for hemophilia A and B

Nicotinic acetylcholine receptors as potential target for treating synucleinopathies

Interim analysis from study of siltuximab in patients with COVID-19 and respiratory complications

Arena reports topline phase I data on controlled-release etrasimod

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...